The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer
Open accessAbstract
Tumor progression and metastasis contribute to the great majority of breast cancer deaths. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are thought to be involved in tumor progression and metastasis. Thus, we determined whether the expression of MMP‐9 and TIMP‐1 is associated with prognosis in breast cancer patients. We measured serum MMP‐9 and TIMP‐1 by enzyme‐linked immunosorbent assay in 60 breast cancer patients, 18 benign breast disease patients and 15 healthy controls. We also evaluated the expression of MMP‐9 and TIMP‐1 protein and mRNA in paraffin‐embedded tumor tissues from the 60 breast cancer patients by immunohistochemistry and in situ hybridization. We then correlated serum and tissue levels of MMP‐9 and TIMP‐1 in breast cancer samples and their expression with patients' clinicopathologic characteristics. We found that serum levels of MMP‐9 and TIMP‐1 were significantly higher in breast cancer patients than in benign breast disease and in healthy controls. High serum levels of MMP‐9 and TIMP‐1 were associated with lymph node metastasis, higher tumor stage and lower relapse‐free and overall survival (OS) rates. Compared to low expression, high tissue expression of MMP‐9 protein was associated with lymph node metastasis and higher tumor stage; and high tissue expression of TIMP‐1 was associated with a lower OS rate. Our findings suggest that MMP‐9 and TIMP‐1 may further be evaluated as biomarkers for predicting progression and prognosis of breast cancer. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
Metastatic potential correlates with enzymatic degradation of basement membrane collagen
Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980) · Nature · doi:10.1038/284067a0 · Cited by 1,768
Fisher, B., Redmond, C., Poisson, R., Margolese, R., Wolmark, N., Wickerham, L., Fisher, E., Deutsch, M., Caplan, R., Pilch, Y., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903303201302 · Cited by 1,587
Proteolytic remodeling of extracellular matrix
Birkedal-Hansen, H. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80116-2 · Cited by 1,074
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
Duffy, M. J., Maguire, T. M., Hill, A., McDermott, E., & O'Higgins, N. (2000) · Breast Cancer Research · doi:10.1186/bcr65 · Cited by 628
Ramos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D. L., & Quigley, J. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13066 · Cited by 591
Significance of ipsilateral breast tumour recurrence after lumpectomy
Fisher, B., Anderson, S., Fisher, E. R., Redmond, C., Wickerham, D. L., Wolmark, N., Mamounas, E. P., Deutsch, M., & Margolese, R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90475-5 · Cited by 556
Veronesi, U., Marubini, E., Vecchio, M. D., Manzari, A., Andreola, S., Greco, M., Luini, A., Merson, M., Saccozzi, R., Rilke, F., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.1.19 · Cited by 505
Metalloproteinases and cancer invasion.
Liotta, L. A., & Stetler‐Stevenson, W. G. (1990) · PubMed · Cited by 397
Pellikainen, J. M., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., & Kosma, V.-M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1061 · Cited by 339
Rolli, M., Fransvea, E., Pilch, J., Saven, A., & Felding-Habermann, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633689100 · Cited by 332
Nikkola, J., Vihinen, P., Vuoristo, M.-S., Kellokumpu-Lehtinen, P., Kähäri, V.-M., & Pyrhönen, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2478 · Cited by 199
Li, H.-C., Cao, D.-C., Liu, Y., Hou, Y.-F., Wu, J., Lu, J.-S., Di, G.-H., Liu, G., Li, F.-M., Ou, Z.-L., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1200-8 · Cited by 181
Somiari, S., Somiari, R. I., Heckman, C., Olsen, C. H., Jordan, R. M., Russell, S. J., & Shriver, C. D. (2006) · International Journal of Cancer · doi:10.1002/ijc.21989 · Cited by 134
Schrohl, A., Holten-Andersen, M., Peters, H. A., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Brünner, N., & Foekens, J. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0360 · Cited by 125
Increased gelatinase-A and gelatinase-B activities in malignantvs. benign breast tumors
Hanemaaijer, R., Verheijen, J. H., Maguire, T. M., Visser, H., Toet, K. H., McDermott, E. W. M., O’Higgins, N. J., & Duffy, M. J. (2000) · International Journal of Cancer · Cited by 118
Ricca, A., Biroccio, A., Bufalo, D. D., Mackay, A. R., Santoni, A., & Cippitelli, M. (2000) · International Journal of Cancer · Cited by 97
Voorzanger‐Rousselot, N., Juillet, F., Mareau, E., Zimmermann, J., Kalebic, T., & Garnero, P. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603285 · Cited by 72
Lee, S., Yoo, H. J., Bae, Y. S., Kim, H. J., & Lee, S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.050 · Cited by 68
Guan, K., Ye, H., Yan, Z., et al. (2003) · Urology · doi:10.1016/s0090-4295(02)02429-9 · Cited by 66
Rauvala, M., Puistola, U., & Turpeenniemi-Hujanen, T. M. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.07.009 · Cited by 64
Morphometric grading of invasive ductal breast cancer. I. Thresholds for nuclear grade
Kronqvist, P., Kuopio, T., & Collan, Y. U. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.582 · Cited by 50
Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients
Giannelli, G., Erriquez, R., Fransvea, E., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20009 · Cited by 36
Nagase, H. (2001) · doi:10.1007/978-1-59259-011-7_2 · Cited by 36
Matrix Metalloproteinase Inhibitors in Cancer Therapy
Clendeninn, N. J., & Appelt, K. (2000) · Humana Press eBooks · doi:10.1385/159259011x · Cited by 31
Cited by
Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer
Roy, R., Yang, J., & Moses, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5556 · Cited by 854
Self-citationMehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D. C., & Radisky, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.1932 · Cited by 368
Barriers to drug delivery in solid tumors
Sriraman, S. K., Aryasomayajula, B., & Torchilin, V. P. (2014) · Tissue Barriers · doi:10.4161/tisb.29528 · Cited by 338
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
Hansson, J., Vasan, R. S., Ärnlöv, J., Ingelsson, E., Lind, L., Larsson, A., Michaëlsson, K., & Sundström, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016185 · Cited by 103
Metadata
- Authors
- Wu, Z., Wu, Q., Yang, J., Wang, H., Ding, X., Yang, F., & Xu, X.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-02-25
- Volume
- 122
- Issue
- 9
- Pages
- 2050-2056
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2083143922
- Cited by
- 268
- References
- 27
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.